nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.116	0.215	CbGbCtD
Topotecan—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.078	0.145	CbGbCtD
Topotecan—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0744	0.139	CbGbCtD
Topotecan—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0663	0.124	CbGbCtD
Topotecan—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.065	0.121	CbGbCtD
Topotecan—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0614	0.114	CbGbCtD
Topotecan—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0389	0.0726	CbGbCtD
Topotecan—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0368	0.0685	CbGbCtD
Topotecan—TOP1MT—respiratory system—chronic obstructive pulmonary disease	0.00866	0.297	CbGeAlD
Topotecan—TOP1MT—lung—chronic obstructive pulmonary disease	0.0046	0.158	CbGeAlD
Topotecan—Irinotecan—ALB—chronic obstructive pulmonary disease	0.00408	1	CrCbGaD
Topotecan—TOP1—bronchus—chronic obstructive pulmonary disease	0.00376	0.129	CbGeAlD
Topotecan—TOP1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00368	0.126	CbGeAlD
Topotecan—TOP1—trachea—chronic obstructive pulmonary disease	0.00338	0.116	CbGeAlD
Topotecan—TOP1—lung—chronic obstructive pulmonary disease	0.00243	0.0832	CbGeAlD
Topotecan—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00118	0.0741	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.0011	0.069	CbGpPWpGaD
Topotecan—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00104	0.0655	CbGpPWpGaD
Topotecan—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00248	CcSEcCtD
Topotecan—Back pain—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00248	CcSEcCtD
Topotecan—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.00102	0.00247	CcSEcCtD
Topotecan—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.00102	0.00247	CcSEcCtD
Topotecan—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00102	0.00245	CcSEcCtD
Topotecan—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.00243	CcSEcCtD
Topotecan—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.00101	0.00242	CcSEcCtD
Topotecan—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.001	0.00242	CcSEcCtD
Topotecan—Dermatitis bullous—Prednisolone—chronic obstructive pulmonary disease	0.001	0.00242	CcSEcCtD
Topotecan—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000993	0.00239	CcSEcCtD
Topotecan—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	0.000989	0.00239	CcSEcCtD
Topotecan—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000988	0.00238	CcSEcCtD
Topotecan—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000988	0.00238	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000981	0.00237	CcSEcCtD
Topotecan—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000973	0.00235	CcSEcCtD
Topotecan—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000973	0.00235	CcSEcCtD
Topotecan—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000973	0.00235	CcSEcCtD
Topotecan—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000967	0.00233	CcSEcCtD
Topotecan—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000967	0.00233	CcSEcCtD
Topotecan—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.00096	0.00232	CcSEcCtD
Topotecan—Malaise—Formoterol—chronic obstructive pulmonary disease	0.00096	0.00232	CcSEcCtD
Topotecan—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000953	0.0023	CcSEcCtD
Topotecan—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000948	0.00229	CcSEcCtD
Topotecan—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000934	0.00225	CcSEcCtD
Topotecan—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000933	0.00225	CcSEcCtD
Topotecan—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00093	0.00224	CcSEcCtD
Topotecan—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000929	0.00224	CcSEcCtD
Topotecan—Cough—Formoterol—chronic obstructive pulmonary disease	0.000929	0.00224	CcSEcCtD
Topotecan—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000921	0.00222	CcSEcCtD
Topotecan—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000919	0.00222	CcSEcCtD
Topotecan—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000911	0.0022	CcSEcCtD
Topotecan—Cough—Montelukast—chronic obstructive pulmonary disease	0.00091	0.0022	CcSEcCtD
Topotecan—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000907	0.00219	CcSEcCtD
Topotecan—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000907	0.00219	CcSEcCtD
Topotecan—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000907	0.00219	CcSEcCtD
Topotecan—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000907	0.00219	CcSEcCtD
Topotecan—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000907	0.00219	CcSEcCtD
Topotecan—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000907	0.00219	CcSEcCtD
Topotecan—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000907	0.00219	CcSEcCtD
Topotecan—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000907	0.00219	CcSEcCtD
Topotecan—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000903	0.00218	CcSEcCtD
Topotecan—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000903	0.00218	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.0009	0.00217	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.0009	0.00217	CcSEcCtD
Topotecan—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.0009	0.00217	CcSEcCtD
Topotecan—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000896	0.00216	CcSEcCtD
Topotecan—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000896	0.00216	CcSEcCtD
Topotecan—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000888	0.00214	CcSEcCtD
Topotecan—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000888	0.00214	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000882	0.00213	CcSEcCtD
Topotecan—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000881	0.00212	CcSEcCtD
Topotecan—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000877	0.00212	CcSEcCtD
Topotecan—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000869	0.0021	CcSEcCtD
Topotecan—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000869	0.0021	CcSEcCtD
Topotecan—Infection—Formoterol—chronic obstructive pulmonary disease	0.000863	0.00208	CcSEcCtD
Topotecan—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000863	0.00208	CcSEcCtD
Topotecan—ABCG2—lung—chronic obstructive pulmonary disease	0.000861	0.0295	CbGeAlD
Topotecan—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000856	0.00207	CcSEcCtD
Topotecan—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000856	0.00207	CcSEcCtD
Topotecan—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000856	0.00207	CcSEcCtD
Topotecan—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000855	0.00206	CcSEcCtD
Topotecan—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000852	0.00206	CcSEcCtD
Topotecan—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000852	0.00206	CcSEcCtD
Topotecan—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000851	0.00205	CcSEcCtD
Topotecan—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000851	0.00205	CcSEcCtD
Topotecan—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.000851	0.0536	CbGpPWpGaD
Topotecan—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000846	0.00204	CcSEcCtD
Topotecan—Infection—Montelukast—chronic obstructive pulmonary disease	0.000846	0.00204	CcSEcCtD
Topotecan—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000844	0.00204	CcSEcCtD
Topotecan—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000844	0.00204	CcSEcCtD
Topotecan—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000841	0.00203	CcSEcCtD
Topotecan—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000835	0.00201	CcSEcCtD
Topotecan—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000833	0.00201	CcSEcCtD
Topotecan—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000832	0.00201	CcSEcCtD
Topotecan—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000827	0.00199	CcSEcCtD
Topotecan—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000821	0.00198	CcSEcCtD
Topotecan—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000815	0.00197	CcSEcCtD
Topotecan—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000808	0.00195	CcSEcCtD
Topotecan—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000805	0.00194	CcSEcCtD
Topotecan—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000799	0.0274	CbGeAlD
Topotecan—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000797	0.00192	CcSEcCtD
Topotecan—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000793	0.00191	CcSEcCtD
Topotecan—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000793	0.00191	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000792	0.00191	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000792	0.00191	CcSEcCtD
Topotecan—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000782	0.00189	CcSEcCtD
Topotecan—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000781	0.00188	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000775	0.00187	CcSEcCtD
Topotecan—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000775	0.00187	CcSEcCtD
Topotecan—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000775	0.00187	CcSEcCtD
Topotecan—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000765	0.00185	CcSEcCtD
Topotecan—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000765	0.00185	CcSEcCtD
Topotecan—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000764	0.00184	CcSEcCtD
Topotecan—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000762	0.00184	CcSEcCtD
Topotecan—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000755	0.00182	CcSEcCtD
Topotecan—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000753	0.00182	CcSEcCtD
Topotecan—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00075	0.00181	CcSEcCtD
Topotecan—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00075	0.00181	CcSEcCtD
Topotecan—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000749	0.00181	CcSEcCtD
Topotecan—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000749	0.00181	CcSEcCtD
Topotecan—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000749	0.00181	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000748	0.0018	CcSEcCtD
Topotecan—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000743	0.00179	CcSEcCtD
Topotecan—Pain—Formoterol—chronic obstructive pulmonary disease	0.000743	0.00179	CcSEcCtD
Topotecan—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000743	0.00179	CcSEcCtD
Topotecan—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000743	0.00179	CcSEcCtD
Topotecan—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000737	0.00178	CcSEcCtD
Topotecan—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000735	0.00177	CcSEcCtD
Topotecan—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000734	0.00177	CcSEcCtD
Topotecan—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000732	0.00176	CcSEcCtD
Topotecan—Pain—Montelukast—chronic obstructive pulmonary disease	0.000728	0.00176	CcSEcCtD
Topotecan—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000726	0.00175	CcSEcCtD
Topotecan—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000723	0.00175	CcSEcCtD
Topotecan—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000722	0.00174	CcSEcCtD
Topotecan—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00072	0.00174	CcSEcCtD
Topotecan—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000719	0.00174	CcSEcCtD
Topotecan—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000716	0.00173	CcSEcCtD
Topotecan—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000716	0.00173	CcSEcCtD
Topotecan—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000715	0.00173	CcSEcCtD
Topotecan—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000713	0.00172	CcSEcCtD
Topotecan—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000712	0.00172	CcSEcCtD
Topotecan—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000711	0.00171	CcSEcCtD
Topotecan—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000711	0.00171	CcSEcCtD
Topotecan—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.00071	0.00171	CcSEcCtD
Topotecan—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000708	0.00171	CcSEcCtD
Topotecan—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000707	0.00171	CcSEcCtD
Topotecan—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000702	0.00169	CcSEcCtD
Topotecan—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000702	0.00169	CcSEcCtD
Topotecan—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000696	0.00168	CcSEcCtD
Topotecan—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.00069	0.00167	CcSEcCtD
Topotecan—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.00069	0.00167	CcSEcCtD
Topotecan—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000687	0.00166	CcSEcCtD
Topotecan—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000687	0.00166	CcSEcCtD
Topotecan—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000687	0.00166	CcSEcCtD
Topotecan—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000687	0.00166	CcSEcCtD
Topotecan—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000685	0.00165	CcSEcCtD
Topotecan—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000679	0.00164	CcSEcCtD
Topotecan—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000678	0.00164	CcSEcCtD
Topotecan—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000678	0.00164	CcSEcCtD
Topotecan—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000676	0.00163	CcSEcCtD
Topotecan—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000676	0.00163	CcSEcCtD
Topotecan—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000675	0.00163	CcSEcCtD
Topotecan—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000673	0.00162	CcSEcCtD
Topotecan—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000673	0.00162	CcSEcCtD
Topotecan—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000671	0.00162	CcSEcCtD
Topotecan—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000666	0.00161	CcSEcCtD
Topotecan—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000662	0.0016	CcSEcCtD
Topotecan—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000662	0.0016	CcSEcCtD
Topotecan—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000652	0.00157	CcSEcCtD
Topotecan—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000649	0.00156	CcSEcCtD
Topotecan—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000649	0.00156	CcSEcCtD
Topotecan—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00064	0.00154	CcSEcCtD
Topotecan—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00064	0.00154	CcSEcCtD
Topotecan—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00064	0.00154	CcSEcCtD
Topotecan—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000627	0.00151	CcSEcCtD
Topotecan—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000623	0.0015	CcSEcCtD
Topotecan—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000623	0.0015	CcSEcCtD
Topotecan—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000615	0.00148	CcSEcCtD
Topotecan—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000615	0.00148	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000614	0.00148	CcSEcCtD
Topotecan—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000611	0.00147	CcSEcCtD
Topotecan—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000605	0.00146	CcSEcCtD
Topotecan—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000602	0.00145	CcSEcCtD
Topotecan—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000595	0.00143	CcSEcCtD
Topotecan—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000595	0.00143	CcSEcCtD
Topotecan—ABCB1—trachea—chronic obstructive pulmonary disease	0.000591	0.0202	CbGeAlD
Topotecan—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000589	0.00142	CcSEcCtD
Topotecan—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000582	0.00141	CcSEcCtD
Topotecan—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000581	0.0014	CcSEcCtD
Topotecan—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000575	0.00139	CcSEcCtD
Topotecan—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000575	0.00139	CcSEcCtD
Topotecan—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000563	0.00136	CcSEcCtD
Topotecan—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000562	0.00136	CcSEcCtD
Topotecan—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000561	0.00135	CcSEcCtD
Topotecan—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000553	0.00133	CcSEcCtD
Topotecan—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000553	0.00133	CcSEcCtD
Topotecan—Rash—Formoterol—chronic obstructive pulmonary disease	0.000548	0.00132	CcSEcCtD
Topotecan—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000548	0.00132	CcSEcCtD
Topotecan—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000547	0.00132	CcSEcCtD
Topotecan—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000547	0.00132	CcSEcCtD
Topotecan—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000547	0.00132	CcSEcCtD
Topotecan—Headache—Formoterol—chronic obstructive pulmonary disease	0.000544	0.00131	CcSEcCtD
Topotecan—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000544	0.00131	CcSEcCtD
Topotecan—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000543	0.00131	CcSEcCtD
Topotecan—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000541	0.00131	CcSEcCtD
Topotecan—Rash—Montelukast—chronic obstructive pulmonary disease	0.000537	0.00129	CcSEcCtD
Topotecan—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000536	0.00129	CcSEcCtD
Topotecan—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000535	0.00129	CcSEcCtD
Topotecan—Headache—Montelukast—chronic obstructive pulmonary disease	0.000533	0.00129	CcSEcCtD
Topotecan—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000527	0.00127	CcSEcCtD
Topotecan—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000526	0.00127	CcSEcCtD
Topotecan—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000522	0.00126	CcSEcCtD
Topotecan—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.00052	0.00125	CcSEcCtD
Topotecan—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000517	0.00125	CcSEcCtD
Topotecan—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000517	0.00125	CcSEcCtD
Topotecan—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000516	0.00125	CcSEcCtD
Topotecan—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000516	0.00125	CcSEcCtD
Topotecan—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000514	0.00124	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—SLC6A4—chronic obstructive pulmonary disease	0.000514	0.0323	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—MMP14—chronic obstructive pulmonary disease	0.000507	0.0319	CbGpPWpGaD
Topotecan—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000506	0.00122	CcSEcCtD
Topotecan—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000487	0.00118	CcSEcCtD
Topotecan—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000485	0.00117	CcSEcCtD
Topotecan—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000484	0.00117	CcSEcCtD
Topotecan—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000481	0.00116	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000472	0.0297	CbGpPWpGaD
Topotecan—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000471	0.00114	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.00047	0.0296	CbGpPWpGaD
Topotecan—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000455	0.0011	CcSEcCtD
Topotecan—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000437	0.00105	CcSEcCtD
Topotecan—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000435	0.00105	CcSEcCtD
Topotecan—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000432	0.0272	CbGpPWpGaD
Topotecan—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000425	0.00103	CcSEcCtD
Topotecan—ABCB1—lung—chronic obstructive pulmonary disease	0.000424	0.0145	CbGeAlD
Topotecan—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000423	0.00102	CcSEcCtD
Topotecan—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000419	0.00101	CcSEcCtD
Topotecan—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000402	0.000971	CcSEcCtD
Topotecan—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000389	0.000938	CcSEcCtD
Topotecan—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000388	0.000936	CcSEcCtD
Topotecan—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000387	0.000934	CcSEcCtD
Topotecan—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000383	0.000924	CcSEcCtD
Topotecan—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000378	0.000912	CcSEcCtD
Topotecan—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000374	0.000902	CcSEcCtD
Topotecan—TOP1—Caspase Cascade in Apoptosis—TNF—chronic obstructive pulmonary disease	0.000372	0.0234	CbGpPWpGaD
Topotecan—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000357	0.000861	CcSEcCtD
Topotecan—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000357	0.000861	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000354	0.000855	CcSEcCtD
Topotecan—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000352	0.00085	CcSEcCtD
Topotecan—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000347	0.000837	CcSEcCtD
Topotecan—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000342	0.000825	CcSEcCtD
Topotecan—Infection—Prednisone—chronic obstructive pulmonary disease	0.00034	0.00082	CcSEcCtD
Topotecan—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000335	0.000809	CcSEcCtD
Topotecan—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000332	0.000801	CcSEcCtD
Topotecan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000331	0.0208	CbGpPWpGaD
Topotecan—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000331	0.000798	CcSEcCtD
Topotecan—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000326	0.000786	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000312	0.000752	CcSEcCtD
Topotecan—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000311	0.000751	CcSEcCtD
Topotecan—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000307	0.000741	CcSEcCtD
Topotecan—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000301	0.000726	CcSEcCtD
Topotecan—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000297	0.000717	CcSEcCtD
Topotecan—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000297	0.000716	CcSEcCtD
Topotecan—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000296	0.000715	CcSEcCtD
Topotecan—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000295	0.000711	CcSEcCtD
Topotecan—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000295	0.000711	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	0.000293	0.0184	CbGpPWpGaD
Topotecan—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000292	0.000706	CcSEcCtD
Topotecan—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000282	0.00068	CcSEcCtD
Topotecan—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.00028	0.000675	CcSEcCtD
Topotecan—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.00028	0.000674	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	0.000273	0.0172	CbGpPWpGaD
Topotecan—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000272	0.000655	CcSEcCtD
Topotecan—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.00027	0.000652	CcSEcCtD
Topotecan—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.00027	0.000652	CcSEcCtD
Topotecan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000257	0.0162	CbGpPWpGaD
Topotecan—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000252	0.000608	CcSEcCtD
Topotecan—ABCG2—Iron uptake and transport—HMOX1—chronic obstructive pulmonary disease	0.00025	0.0157	CbGpPWpGaD
Topotecan—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000245	0.000592	CcSEcCtD
Topotecan—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000242	0.000584	CcSEcCtD
Topotecan—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000234	0.000565	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	0.00023	0.0145	CbGpPWpGaD
Topotecan—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000226	0.000546	CcSEcCtD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000223	0.014	CbGpPWpGaD
Topotecan—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000217	0.000525	CcSEcCtD
Topotecan—Rash—Prednisone—chronic obstructive pulmonary disease	0.000216	0.00052	CcSEcCtD
Topotecan—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000215	0.00052	CcSEcCtD
Topotecan—Headache—Prednisone—chronic obstructive pulmonary disease	0.000214	0.000517	CcSEcCtD
Topotecan—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000203	0.00049	CcSEcCtD
Topotecan—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000203	0.0128	CbGpPWpGaD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000198	0.0125	CbGpPWpGaD
Topotecan—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000194	0.0122	CbGpPWpGaD
Topotecan—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000187	0.0117	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000181	0.0114	CbGpPWpGaD
Topotecan—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000179	0.0113	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000177	0.0112	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000167	0.0105	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000165	0.0104	CbGpPWpGaD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000162	0.0102	CbGpPWpGaD
Topotecan—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000156	0.00979	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000153	0.00965	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	0.000151	0.00952	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.000148	0.00933	CbGpPWpGaD
Topotecan—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000147	0.00928	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	0.000141	0.00889	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000137	0.0086	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000136	0.00855	CbGpPWpGaD
Topotecan—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000136	0.00853	CbGpPWpGaD
Topotecan—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00013	0.00821	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000127	0.00797	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	0.000125	0.00785	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	0.000124	0.00784	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000124	0.00778	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000122	0.00768	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	0.00012	0.00752	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000114	0.00716	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000113	0.0071	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	0.000109	0.00688	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000107	0.00671	CbGpPWpGaD
Topotecan—ABCG2—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	9.65e-05	0.00607	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	9.58e-05	0.00603	CbGpPWpGaD
Topotecan—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	9.58e-05	0.00603	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	9.03e-05	0.00569	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	8.29e-05	0.00522	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	7.92e-05	0.00499	CbGpPWpGaD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	7.75e-05	0.00488	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	7.73e-05	0.00487	CbGpPWpGaD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	7.65e-05	0.00481	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	7.39e-05	0.00465	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	7.35e-05	0.00462	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	7.34e-05	0.00462	CbGpPWpGaD
Topotecan—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	6.96e-05	0.00438	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	6.85e-05	0.00431	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	6.28e-05	0.00395	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—APIP—chronic obstructive pulmonary disease	5.85e-05	0.00368	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	5.77e-05	0.00363	CbGpPWpGaD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	5.63e-05	0.00354	CbGpPWpGaD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	5.56e-05	0.0035	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	4.56e-05	0.00287	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	4.23e-05	0.00266	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	4.06e-05	0.00255	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.01e-05	0.00253	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	3.97e-05	0.0025	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	3.97e-05	0.0025	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.88e-05	0.00244	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GC—chronic obstructive pulmonary disease	3.77e-05	0.00237	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.51e-05	0.00221	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	3.43e-05	0.00216	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.34e-05	0.0021	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.29e-05	0.00207	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	3.17e-05	0.00199	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	3.15e-05	0.00198	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.01e-05	0.00189	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	2.94e-05	0.00185	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.78e-05	0.00175	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.74e-05	0.00173	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.56e-05	0.00161	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.52e-05	0.00159	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.42e-05	0.00153	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.39e-05	0.0015	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.1e-05	0.00132	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.06e-05	0.0013	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	2.04e-05	0.00128	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GCLC—chronic obstructive pulmonary disease	2.04e-05	0.00128	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.95e-05	0.00123	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.9e-05	0.00119	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.86e-05	0.00117	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.81e-05	0.00114	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.71e-05	0.00108	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.69e-05	0.00107	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.63e-05	0.00102	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.56e-05	0.000979	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.53e-05	0.00096	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.45e-05	0.000914	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.43e-05	0.000899	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.41e-05	0.000887	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.31e-05	0.000826	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.29e-05	0.000813	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.28e-05	0.000806	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.26e-05	0.000791	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.24e-05	0.000783	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.17e-05	0.000735	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.11e-05	0.000701	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.1e-05	0.000693	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.01e-05	0.000633	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	9.77e-06	0.000615	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.26e-06	0.000583	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	8.46e-06	0.000532	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	8.09e-06	0.000509	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.72e-06	0.000486	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.62e-06	0.000479	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.1e-06	0.000447	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.87e-06	0.000432	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	6.79e-06	0.000427	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.73e-06	0.000423	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	6.19e-06	0.00039	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.71e-06	0.000359	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.76e-06	0.000299	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.69e-06	0.000295	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	4.57e-06	0.000288	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.37e-06	0.000275	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.37e-06	0.000275	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.15e-06	0.000261	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.82e-06	0.000177	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.7e-06	0.00017	CbGpPWpGaD
